At a dose of 2.0 mg/kg administered every 2 weeks, the confirmed objective response rates were 42.9% for patients with HER2-positive BC and 33.3% for patients with HER2-low-expression BC, with median PFS durations of 5.7 and 5.1 months, respectively. Here, ERBB2 is linked to breast cancer.